
Robert Kuok Retains No. 1 Spot On 2025 Forbes List of Malaysia's 50 Richest
SINGAPORE (April 17, 2025) – Malaysia's buoyant IPO market saw 55 listings in 2024, however the benchmark stock index remained sluggish and was pushed down further after the U.S. tariff shock. But a stronger ringgit, up more than 5% in the past 12 months, helped to lift the collective wealth of tycoons on the 2025 Forbes list of Malaysia's 50 Richest to US$90 billion, from $83.4 billion last year. The complete list can be found here, as well as in the April/May issue of Forbes Asia.
The ranks of the three richest Malaysians were unchanged from a year ago. Business legend Robert Kuok remained unshakable at the top at age 101, with a net worth of $11.4 billion. The agribusiness-to-hotels empire under his Kuok Group has plans for an ambitious data center buildout in Malaysia's Johor state.
Hong Leong group patriarch Quek Leng Chan strengthened his position as the second-richest person with a $1 billion jump in his net worth to $9.8 billion, buoyed by robust sales at his family's finance-to-food conglomerate. The Teh siblings, heirs to the Public Bank fortune, retained the third spot with their wealth rising 9% to $5.9 billion. Aluminium magnates Koon Poh Keong & siblings moved up one spot to No. 4 after a modest boost took their net worth to $5.4 billion.
Overall, 30 people are better off from a year ago. Another gainer was Jeffrey Cheah (No. 9), who added $600 million to take his net worth tally to $3 billion on rising shares of his property conglomerate Sunway, which is planning to list its healthcare unit next year.
There are three new entrants to the ranks. Debuting on the list at No. 5 with $5.3 billion is the Krishnan family, heirs of a telecom-to-energy empire built by reclusive billionaire Ananda Krishnan, who died in November at age 86. Also new to the list is Lee Thiam Wah (No. 8, $3.5 billion), founder of 99 Speed Mart Retail Holdings, the country's largest minimart chain by number of stores. Lee became a billionaire after taking his company public in September, raising $532 million in the country's biggest IPO in seven years. Another fresh face is that of former police officer Tan Boon Hock (No. 40, $490 million), whose portfolio includes a chain of laser eye surgery clinics and a company specializing in AI-powered traffic management systems.
The sole returnee is mall magnate Desmond Lim Siew Choon (No. 44, $420 million), whose Pavilion Reit has benefited from higher rentals.
The minimum net worth to make the list rose slightly to $335 million from $320 million.
The top 10 richest in Malaysia are:
This list was compiled using shareholding and financial information obtained from the families and individuals, stock exchanges, annual reports, analysts, government agencies and other sources. Net worths were based on stock prices and exchange rates as of the close of markets on April 7, 2025, and private companies were valued based on similar companies that are publicly traded. Real-time net worths on Forbes.com may reflect different valuations. The ranking lists both individual and family fortunes, including those shared among relatives and may differ from the World's Billionaires List, which includes individual fortunes with net worths as of March 7. The list can also include foreign citizens with business, residential or other ties to the country, or citizens who don't reside in the country but have significant business or other ties to the country.
For more information, visit www.forbes.com/malaysia
About Forbes
Forbes champions success by celebrating those who have made it, and those who aspire to make it. Forbes convenes and curates the most influential leaders and entrepreneurs who are driving change, transforming business and making a significant impact on the world. The Forbes brand today reaches more than 140 million people worldwide through its trusted journalism, signature LIVE and Forbes Virtual events, custom marketing programs and 42 licensed local editions in 68 countries. Forbes Media's brand extensions include real estate, education and financial services license agreements.
For media queries, please contact:
Catherine Ong Associates
Catherine Ong, cell: +65 9697 0007, Email: cath@catherineong.com
Chenxi Wang, cell: +65 8187 3215, Email: chenxi@catherineong.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Tensions between the US and China have delayed Apple's AI rollout in China, FT reports
The Financial Times claims that the Cyberspace Administration of China (CAC) is delaying the introduction of AI services by Apple Inc. (NASDAQ:AAPL) and Alibaba in China. A wide view of an Apple store, showing the range of products the company offers. Their February deal to incorporate AI technologies into iPhones in China is on hold due to geopolitical tensions resulting from U.S. President Donald Trump's trade war. Consumer-facing AI technologies need regulatory permission, and the CAC has not yet given its approval to these applications. The business is facing diminishing iPhone sales in China due to increased local competition, particularly from Huawei, which has integrated DeepSeek's AI models into its handsets. The firm is at a disadvantage to its AI-enabled Android rivals due to its lack of sophisticated AI technologies, such as ChatGPT-powered features and Apple Inc. (NASDAQ:AAPL)'s postponed "Apple Intelligence." More pressure is added by Trump's recent pronouncement of a 25% tariff on iPhones sold in the US that are not produced locally. New software improvements are anticipated during Apple Inc. (NASDAQ:AAPL)'s WWDC event, which takes place from June 9–13. While we acknowledge the potential of AAPL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
HIVE Digital Capacity Crosses 10 EH/s in May, Aims to More Than Double That by Year-End
Bitcoin miner HIVE Digital Technologies (HIVE) has surpassed 10 exahash per second (EH/s) in hashrate capacity, a 58% increase from April, driven by the launch of a 100-megawatt hydro-powered site in Paraguay. The company said in a press release on Friday that it's on track to reach 25 EH/s by the end of 2025. The firm mined 139 bitcoin in May, or an average rate of 4.5 BTC per day. Peak capacity hit 10.4 EH/s while average hashrate for the month stood at 8.5 EH/s. HIVE said its fleet efficiency remained steady at around 20 joules per terahash (J/TH), and its network share now exceeds 1% of global Bitcoin mining power. The new facility in Paraguay reflects a broader trend in the mining industry: the race to deploy next-generation ASIC miners rapidly and at scale in regions with abundant renewable power. Co-founder Frank Holmes emphasized the company's speed and flexibility, pointing to its Buzz HPC division, which supports AI cloud infrastructure alongside Bitcoin mining. CEO Aydin Kilic said the company's goal for the summer is 18 EH/s, and that fleet upgrades should allow for a daily BTC output of over 12 by the fourth quarter — potentially at a production cost below $50,000 per coin. HIVE operates facilities in Canada, Sweden and Paraguay, powered entirely by hydroelectricity. The company was the first publicly listed crypto miner on the TSX Venture Exchange in 2017. HIVE shares are higher by 13% in New York trade on Friday as the mining sector rallies alongside bitcoin's gain to above $105,000.

Associated Press
3 hours ago
- Associated Press
Oncoscope Officially Launches, Ushering in a New Era of Real Time Oncology Intelligence
06/06/2025, Miami, Florida // PRODIGY: Feature Story // Anna Forsythe, founder of Oncoscope-AI (source: Oncoscope-AI) Oncoscope-AI, a revolutionary oncology intelligence platform, has officially launched following a successful beta phase and over a year of strategic development that involved extensive conversations with practicing oncologists. The platform, which delivers real-time, human-curated cancer insights enhanced by artificial intelligence, is now live and available free of charge to verified healthcare professionals worldwide. Founded by Anna Forsythe, a pharmacist, health economist, and seasoned pharmaceutical executive, Oncoscope addresses a critical gap in oncology care. It gives clinicians instant access to the most current treatment data, FDA approvals, and guideline-aligned information, consolidated into one user-friendly platform. 'Doctors do not need more data. They need the right information, at the right time, in a format they can use to make better decisions for their patients,' said Forsythe. 'Oncoscope provides that clarity. It is a living library of oncology, curated by experts and built to save lives.' Unlike generic AI tools or static databases, Oncoscope uses trained AI to scan thousands of oncology publications and filters them through a rigorous, evidence-based framework. Each entry is cross-referenced with clinical guidelines and regulatory approvals to ensure usability and relevance. All of the results are carefully scrutinized by a team of experienced researchers. Currently, the platform supports breast and lung cancer, with prostate, bladder, colon, and rectal modules rolling out in the coming months. The process is intuitive. Physicians answer three clinical questions—cancer stage, genetic markers, and prior treatments—and receive a personalized, actionable summary. Each recommended article includes survival data, progression insights, treatment efficacy, and toxicity, extracted across 32 key clinical parameters. 'The result is something physicians can actually use in the moment,' said Forsythe. 'It takes three clicks to go from a patient in the room to the most up-to-date evidence in the field.' Access to Oncoscope is free for verified healthcare professionals, including physicians, nurses, pharmacists, genetic counselors, and physician assistants. Non-verified users, such as those in finance or consulting, can purchase limited access at a monthly rate, restricted to a single cancer type. This structure reflects the company's commitment to empowering front-line clinicians with better tools—without barriers. Forsythe, who previously founded and sold a successful health economics company serving global pharmaceutical clients, brings a rare combination of clinical, technical, and business expertise to this venture. She sees Oncoscope not only as a tool, but as a mission. 'This platform was born from both professional insight and personal urgency,' she said. 'Too many patients are still receiving outdated treatments, simply because their doctors do not have time to stay current. I realized I had the knowledge, the team, and the experience to fix that.' With a lean team, strategic vision, and a rapidly growing user base, Oncoscope is poised to become a trusted global resource in cancer treatment. 'We are not just a tech company,' said Forsythe. 'We are part of the oncology ecosystem. And we are here to help doctors deliver the best care possible.' For more information, visit Media Contact: Name - Anna Forsythe Email - [email protected] Source published by Submit Press Release >> Oncoscope Officially Launches, Ushering in a New Era of Real Time Oncology Intelligence